Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI

(SAN)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
08/19/2019 08/20/2019 08/21/2019 08/22/2019 08/23/2019 Date
77.24(c) 77.06(c) 77.93(c) 77.02(c) 76.73(c) Last
2 329 059 2 217 389 1 483 352 1 922 119 1 823 197 Volume
+1.64% -0.23% +1.13% -1.17% -0.38% Change
More quotes
Financials (EUR)
Sales 2019 36 243 M
EBIT 2019 9 446 M
Net income 2019 4 174 M
Debt 2019 14 643 M
Yield 2019 4,11%
Sales 2020 37 654 M
EBIT 2020 10 074 M
Net income 2020 5 712 M
Debt 2020 11 933 M
Yield 2020 4,29%
P/E ratio 2019 25,1x
P/E ratio 2020 17,0x
EV / Sales2019 3,05x
EV / Sales2020 2,86x
Capitalization 95 912 M
More Financials
Company
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (85.1%): for the treatment of cardio-vascular diseases, thrombosis, central nervous system disorders (insomnia, multiple sclerosis, epilepsy), cancers, allergies,... 
Sector
Pharmaceuticals
Calendar
09/09Presentation
More about the company
Surperformance© ratings of Sanofi
Trading Rating : Investor Rating :
More Ratings
Latest news on SANOFI
06:19aSANOFI : and Sehat Kahani to improve diabetes care
AQ
08/22SANOFI : DOH swats down Sanofi appeal to lift Dengvaxia ban
AQ
08/20BAYER : Elanco to become No.2 in animal health with $7.6 billion Bayer deal
RE
08/20BAYER : Elanco to become No.2 in animal health with $7.6 billion Bayer deal
RE
08/16SANOFI AVENTIS : Board of directors meeting of Sanofi - Aventis Pakistan Limited
AQ
08/12REGENERON PHARMACEUTICALS : Two Experimental Ebola Drugs Reduce Mortality Rate
DJ
08/12United States Insulin Delivery Devices Market is Anticipated to Reach US$ 6 B..
AQ
08/12No-deal Brexit could deepen Europe's shortage of medicines - experts
RE
08/07SANOFI : DOH won't rush review on Dengvaxia
AQ
08/07REGENERON PHARMACEUTICALS : Dupixent Showed Positive Topline Results in Phase 3 ..
AQ
More news
Analyst Recommendations on SANOFI
More recommendations
Stock Trading Strategies
SANOFI - 08/02
No turn-around in sight
BUY
More Stock Trading Analysis
Sector news : Pharmaceuticals - NEC
08/23ALLERGAN : Form 8.3 -
DJ
08/23NOVARTIS : Delay on Data Manipulation Probed
DJ
08/23GLAXOSMITHKLINE : Achieves Positive Results Blood Cancer Treatment Study
DJ
08/22Alexion Up Nearly 8%, on Pace for Largest Percent Increase Since April 2018 -..
DJ
08/22ABBVIE : Form 8.3 -
DJ
More sector news : Pharmaceuticals - NEC
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 87,32  €
Last Close Price 76,73  €
Spread / Highest target 30,3%
Spread / Average Target 13,8%
Spread / Lowest Target 2,96%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Ameet Nathwani Executive Vice President-Medical Affairs
John C. Reed Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI1.41%106 841
JOHNSON & JOHNSON-1.02%346 443
ROCHE HOLDING LTD.11.71%236 383
MERCK AND COMPANY11.16%222 036
NOVARTIS18.13%204 408
PFIZER-19.63%194 029